Ani Pharmaceutic SEC Filings

Jeanne A. Thoma, a director of ANI Pharmaceuticals, Inc. (ANIP), reported two open-market sales of the issuer's common stock on 08/18/2025. The Form 4 shows a sale of 6,865 shares at a weighted-average price of $89.76 and a sale of 14,675 shares at a weighted-average price of $88.87, both reported as direct beneficial ownership dispositions. The explanatory remarks state the first block traded between $89.75 and $89.90 and the second between $88.74 and $89.39; the signature date on the filing is 08/20/2025. The form lists post-transaction beneficial ownership of 38,080 shares and 23,405 shares on the respective lines, and indicates the reporting person files as an individual and is a director of the issuer.

Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 5,421 shares of the issuer's common stock on 08/20/2025 at a weighted average sales price of $89.73 per share, reducing his direct holdings to 29,952 shares. The Form 4 notes the shares were sold in multiple trades at prices ranging from $89.27 to $90.18. The filing was signed on behalf of Mr. Pera by an attorney-in-fact.

Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 5,421 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $486,406.81. The filing states the shares represent restricted stock acquired in two grants: 5,000 shares on 03/23/2022 and 421 shares on 08/05/2022, with corresponding payment dates matching acquisition dates. The sale is approximately dated 08/20/2025 and listed for execution on NASDAQ. The filer certifies they are not aware of undisclosed material adverse information about the issuer. No securities of the issuer were reported sold by the filer in the past three months.

ANI Pharmaceuticals (ANIP) Form 144 shows a proposed sale of 14,675 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $1,304,170.19, and an approximate sale date of 08/18/2025. The issuer has 21,688,772 shares outstanding. The filing lists acquisition details for the securities being sold: 1,072 shares vested 12/20/2021, 3,554 shares vested 08/31/2022, and 10,049 shares vested 05/09/2023, all described as restricted stock vesting under a registered plan for services rendered. The filing also records a sale on 08/18/2025 by Jeanne A Thoma of 6,865 shares for gross proceeds of $616,223.68. The filer attests there is no undisclosed material adverse information.

ANI Pharmaceuticals director Matthew J. Leonard reported the sale of 6,937 shares of ANIP common stock on 08/18/2025. The shares were sold in multiple trades at prices ranging from $87.66 to $88.36, with a weighted-average sale price of $88.17. After the transactions Mr. Leonard beneficially owned 9,392 shares, reported as directly owned. The Form 4 was filed as a single reporting person filing and is signed by an attorney-in-fact on behalf of Mr. Leonard.

This filing documents a routine insider disposition of equity by a director and provides the exact sale quantity, price range, weighted-average price, and resulting beneficial ownership shown on the Form 4.

Insider sale reported: ANI Pharmaceuticals director Patrick D. Walsh disposed of 9,000 shares of ANIP common stock on 08/15/2025 at $89.05 per share, according to this Form 4. After the sale he beneficially owned 70,048 shares. The form was signed by an attorney-in-fact on 08/18/2025. No derivative transactions or additional explanations are disclosed.

ANI Pharmaceuticals insider sales by Shanmugam Muthusamy The filing shows that Shanmugam Muthusamy, a director and an officer (Head of R&D, COO-Novitium Ops), reported sales of ANI Pharmaceuticals (ANIP) common stock on 08/14/2025 and 08/15/2025. On 08/14/2025 he sold 47,010 shares at a weighted average price of $89.48, leaving 584,910 shares reported as beneficially owned through Esjay LLC. On 08/15/2025 he sold 52,990 shares at a weighted average price of $87.15, leaving 531,920 shares reported as beneficially owned through Esjay LLC. The filing also reports indirect ownership of 5,000 shares held by SS Pharma LLC. The statement is signed by attorney-in-fact Meredith W. Cook on 08/18/2025.

ANI Pharmaceuticals insider sale reported. Chad Gassert, SVP - Corporate Development & Strategy, reported a disposition of 20,000 shares of ANI Pharmaceuticals common stock on 08/15/2025 at a weighted-average price of $86.97 per share. Following the reported transactions, the reporting person beneficially owns 173,226 shares indirectly through Chali Properties LLC, over which he holds voting and dispositive power.

The filing clarifies the sale was executed in multiple trades at prices ranging from $86.54 to $88.05. The form is signed by an attorney-in-fact on behalf of Mr. Gassert and lists his role with the company as an officer.

ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.